Trophos gets 1M-euro funding from France's ANR

French biopharmaceutical firm Trophos SA says it has been awarded a 1.0 million-euro ($1.5 million) grant from the country's public research body, the Agence Nationale pour la Recherche (ANR). Trophos said that the funding, which will be awarded over a period of two years, will be used as part of its IRIstop project.

IRIstop is focused on evaluating the ability of the drug candidate TRO40303 to prevent the cellular damage that occurs in preclinical models of both cardiac and cerebral ichemia-reperfusion injury. The work is being conducted in collaboration with researchers at the University of Creteil and Paris Descartes faculte de sciences pharmaceutiques et biologiques de Paris.

Antoine Beret, Trophos' chief executive, welcomed the ANR's support and added that early preclinical studies of TRO40303 suggest that it has considerable commercial potential.